Senomyx — Proxy Contest (April 2017)
37 slides from Senomyx's proxy contest presentation, Apr 25, 2017
Slide 1: Senomyx April Investor Presentation
Senomyx April Investor Presentation April 2017
Slide 2: Forward Looking Statement
Forward Looking Statement These slides accompany an oral presentation by Senomyx, Inc. Information presented in this presentation contains forward- looking statements within the meaning of the Section 27A of the Securities Act of 1933, as amended (the “Securities Act’), ‘Section 21E of the Securitie
Slide 3: Important Additional Information
Important Additional Information ‘Senomys, its directors and certain of its executive officers are participants in the solicitation of proxies from Company shareholders in connection with the matters to be considered at the Company's annual meetingof shareholders scheduled tobe heldon May 11, 2017.
Slide 4: Table of Contents
Table of Contents Company Overview Executive Summary Industry Trends and Challenges Business Model Key Market Opportunities Financial Overview CSNS (A Lack of Value) The Right Leadership and Board
Slide 5: Company Overview
Company Overview @ NASDAQ listed: SNMX e Leading company using proprietary taste receptor technologies to develop novel products for the packaged food, beverage, and ingredient supply industries e Multi-pronged B2B business model generating both development & commercial revenues * World leading food
Slide 6: Company Overview: Senomyx Discovery Advantages
Company Overview: Senomyx Discovery Advantages Taste Panel Utilize sensitive receptor-based assays * Proprietary libraries contain several million samples / extracts * Ability to screen > 40,000 samples / week Optimization guided by assays & taste testing Utilize established regulatory approval path
Slide 7: Executive Summary: Senomyx Board Strategic Initiatives
Executive Summary: Senomyx Board Strategic Initiatives Market/ Strategic Condition SNMX Board Response / Results Consumer sentiment shifting towards natural low/no calorie high intensity sweeteners (HIS) and flavor ingredients Reliance on exclusive collaborations for commercialization to secure non-
Slide 8: Executive Summary: Proxy Contest
Executive Summary: Proxy Contest Acompany positioned to drive revenue growth and long-term value for shareholders - with significant momentum, The ability to further leverage a dual-revenue business model and leading proprietary taste technology (siratose) for future success Acompany that is already
Slide 9: Industry Trends and Challenges
Industry Trends and Challenges ® Global Health Epidemic Obesity — 1.5 billion adults are overweight or obese worldwide * Diabetes - 371 million people living with diabetes worldwide © Sugar Guidelines World Health Organization (WHO) guidelines for sugar intake recommend adults & children reduce dail
Slide 10: Industry Trends and Challenges: Target Markets
Industry Trends and Challenges: Target Markets e Key industry challenges: * Health concerns (e.g., obesity, diabetes, high blood pressure) * Food-related legislation & taxes * Cost & sustainability pressures * Provide great tasting products Global packaged e Carbohydrate Sweeteners ~ $100 billion fo
Slide 11: Business Model: Multiple Sources of Revenue
Business Model: Multiple Sources of Revenue Collaboration Model Access to Senomyx discoveries exchange for R&D funding in R&D Funding Period - Partners evaluate and may select Senomyx products for commercialization Royalty Period - Partners pay royalties on use of selected Senomyx products through p
Slide 12: Business Model: Collaboration Model: Natural Sweet Program
Busin Model: usiness Mode Collaboration Model: Natural Sweet Program © Primary Objectives + Maximize commercial opportunity for programs and products + Generate non-dilutive research funding to support R&D * Create incentive for partners to join syndicate + Reduce reliance on single partner © Collab
Slide 13: Business Model: Collaboration Model: Royalty-based Collaboration
Business Model: Collaboration Model: Royalty-based Collaboration Our flavor ingredients span across an array of industries including food, beverage, oral care, pharmaceutical, and OTC e Sucrose Booster (S6973) commercialized in variety of categories * Includes ready-to-drink & powdered beverages, da
Slide 14: Business Model: Direct Sales Model: Flavor Industry Overview
Business Model: Direct Sales Model: Flavor Industry Overview sendmyx. Foods Beverages Personal Pharma/ Care OTC Healthcare © Flavor Industry: * $12 billion annual sales * Top 12 companies represent 82% of market * Industry Leaders: Givaudan, Firmenich, IFF & Symrise (56% of market) * Customer base:
Slide 15: Business Model: Direct Sales Model: Pipeline
Business Model: Direct Sales Model: Pipeline >100 Flavor House (FH) Meetings 83 FH MTA Evaluations 16 FH “Wins” = an order of sufficient volume to support use in a commercial (CPG) product 126 CPG “Pull” Visits *Metrics as of 3/02/17
Slide 16: Key Market Opportunities: Siratose Discovery Process
Key Market Opportunities: Siratose Discovery Process Screened > 3 Million Natural Samples Identified ~ 300 Natural Sweeteners 36 distinct families (Monk Fruit one family) Evaluated Monk Fruit Sweetener family — selected best in class for development Selected siratose for developme! 16
Slide 17: Key Market Opportunities: Siratose vs. Rebaudioside-A (Stevia)
Key Market Opportunities: Siratose vs. Rebaudioside-A (Stevia) Siratose Reboudioside 4 Comments Stevia Potency V Requires 33% - 50% less Taste Quality V Less bitterness, off-tastes subiy ie ene Solubility y Greater margin over use level Cost-in-Use V Targeting lower cost/kg than Stevia Regulatory a]
Slide 18: Key Market Opportunities: Siratose Next Steps
Key Market Opportunities: Siratose Next Steps e Intellectual Property Strategy - continue implementation * Key components: siratose structure, unique properties (use), fermentation process © Commercial Scale Manufacturing - anticipated through fermentation, with strain development currently in progr
Slide 19: Financial Overview
Financial Overview
Slide 20: Financial Overview: Results
Financial Overview: Results © Balance Sheet and sources of funding + $12.4 million in cash & highly liquid investments (at 12/31/16) + Sources of cash - Committed R&D funding ($17.5 million as of 12/31/16) + Includes $6 million per year annual R&D funding under PepsiCo Sweet Program Collaboration -
Slide 21: Financial Overview: Senomyx's Plan Is Working
Financial Overview: Senomyx’s Plan Is Working Strong year-over-year revenue growth, with commercial revenues up 31% to $9.2 million in the fiscal year ended December 31, 2016 Commercial revenues delivered high gross margins at 88% during 2016 Q1 2017 direct sales are more than double the previous hi
Slide 22: CSNS (A Lack of Value)
CSNS (A Lack of Value)
Slide 23: CSNS (A Lack of Value): No Plan to Create Value
CSNS (A Lack of Value): No Plan to Create Value Dissident Proposal Senomyx believes the election of CSNS's nominees would itreparabiy disrupt the current strategy in motion and put vital Replace entire business relationships at risk. Board through — Replaces highty-qualfied directors who now the ind
Slide 24: CSNS (A Lack of Value): Is This a Plan?
CSNS (A Lack of Value): Is This a Plan? INTENDED CHANGES The Nominees plan to create a detailed analysis and forecast of each business unit of Senomyx. The analysis and forecast will focus on maximizing the profitability of each business unit within the Company. The Nominees plan to ‘use this inform
Slide 25: CSNS (A Lack of Value): Not Truly Independent, Not Qualified
CSNS (A Lack of Value): : Not Truly Independent, Not Qualified The dissident slate is full of interconnected nominees with very limited industry experience Not Truly Independent Charles Gillman is financing a change in control attempt, nominating a slew of directors he has served on boards with 6 of
Slide 26: CSNS (A Lack of Value): Independent or Highly Interconnected?
CSNS (A Lack of Value): Independent or Highly Interconnected? The unqualified dissident nominees are highly interconnected with proxy fight soar financial backer Gillman at the center. aan a \ —— novatign ba a ‘Sources: Bloomberg, ESSX proxy fling 5/7/15, 26 EDGAR, Novation Companies, Linkedin, OT
Slide 27: CSNS (A Lack of Value): Fact vs. Fiction
CSNS (A Lack of Value): Fact vs. Fiction What CSNS says: “We have identified and are nominating seven highly qualified directors who would bring substantial expertise and deep experience to the Board to act on the enormous value creation opportunity present at Senomyx today.” What they choose to lea
Slide 28: The Right Leadership and Board
The Right Leadership and Board
Slide 29: The Right Leadership: The Right Management Team
I, Poyhonen was prometed to tis curent Peston end ecame 8 member of out Board BF oeders as of anvary 2, 2058. He joined Senomy in Oeober 2008 65 vies Present Bnd chet business oes, was promoted In ‘Apil 2008. to. Vice. Preidnt. and. Chie! Fnandal and Busines Oficer wae named Senior Vice Fresdant Che
Slide 30: The Right Board: Experienced and Highly Qualified
The Right Board: Experienced and Highly Qualified 20 yeersexperience s senior executive steading favor company song {elevorsn pe wh food, overage ang vor supply companies tht have Senetes Senomy. Pozzestesdasp egal govemance and both publi/prvate Qoard experiance Financia and investing experience Bi
Slide 31: The Right Board: Experienced and Highly Qualified
The Right Board: Experienced and Highly Qualified Many of Senomyx’s board members have experience maximizing shareholder value and serving on boards of companies with >$1 billion market capitalization. Dyax Corp. ‘Agouron Pharmaceuticals, Inc. Santarus, Inc. Ardea Biosciences, Inc. ‘Santarus, Inc. C
Slide 32: The Choice for Shareholders is Clear
The Right Leadership and Board: The Choice for Shareholders is Clear The Senomyx Board has taken a number of key strategic initiatives in response to evolving market and strategic conditions, which has positioned the Company to deliver long term value to shareholders. The Senomyx slate of Directors
Slide 33: Back-up Slides
Back-up Slides Material Not for Presentation
Slide 34: Case Study: CompuMed
Case Study: CompuMed In addition to Charles Gillman, four of his CSNS nominees have overseen share price declines during their time serving as CompuMed directors ***Mark Stolper: -60%; Lee Keddie: -50%; David Pointer: -23%; Benjamin Large: -20%*** ° $035 $030 $025 $020 $035 $0.0 $008 $0.00 ‘Stagnati
Slide 35: Case Study: Novation
Case Study: Novation Multiple members of the CSNS slate have presided over long-term value destruction and stagnation at Novation June 2009: Barry Igdaloff, currently $180 Chairman, was named to Novation’s Board of Directors. Share price is down 89% during his tenure. January 2016: Charles Gillman,
Slide 36: Case Study: Essex Rental Corp.
Case Study: Essex Rental Corp. Gillman has a history of supporting nominees who have a clear track record of destroying shareholder value ne ‘April 2015: The Chatman of ESSX's Board met with Charles Gillman, who represented himsetf as a representative of Lee Keddie to discuss Keddie’s self-nominatio
Slide 37: Contact Information
Contact Information Shareholders Ifyou have any questions or require any assistance with respect to voting ‘your shares, please contact the Company's proxy solicitor at the contact listed below: MORROW SODALI 470 West Avenue ‘Stamford, CT 06902 Shareholders Call Toll Free: (800) 682-6200 Banks and B